Gulfo Adele M. — SEC Form 4 filings
SEC reporting owner CIK 1647102. 22 Form 4 filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2024-02-15 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 30.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enpro Inc. (NPO) | Director | 18 | — | — | 24 |
| NewAmsterdam Pharma Co N.V. (NAMS) | Director | 2 | — | — | 4 |
| Tyra Biosciences, Inc. (TYRA) | Director | 2 | — | — | 2 |
Form 4 filings — Gulfo Adele M.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Enpro Inc. (NPO) | Grant/award (A): 5 (derivative) @ $287.16 · Grant/award (A): 0.57 (derivative) @ $287.16 | EDGAR |
| 2026-06-18 | 4 | Enpro Inc. (NPO) | Grant/award (A): 4 (derivative) @ $363.62 · Grant/award (A): 0.45 (derivative) @ $363.62 | EDGAR |
| 2026-06-01 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 13,160 (derivative) @ $0 | EDGAR |
| 2026-03-19 | 4 | Enpro Inc. (NPO) | Grant/award (A): 5 (derivative) @ $250.59 · Grant/award (A): 0.66 (derivative) @ $250.59 | EDGAR |
| 2026-02-12 | 4 | Enpro Inc. (NPO) | Grant/award (A): 567 @ $246.91 | EDGAR |
| 2026-01-09 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 3,400 · Grant/award (A): 15,300 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Enpro Inc. (NPO) | Grant/award (A): 116.75 (derivative) @ $214.13 | EDGAR |
| 2025-12-18 | 4 | Enpro Inc. (NPO) | Grant/award (A): 6 (derivative) @ $205.19 · Grant/award (A): 0.60 (derivative) @ $205.19 | EDGAR |
| 2025-10-01 | 4 | Enpro Inc. (NPO) | Grant/award (A): 110.62 (derivative) @ $226 | EDGAR |
| 2025-09-18 | 4 | Enpro Inc. (NPO) | Grant/award (A): 6 (derivative) @ $217.89 · Grant/award (A): 0.41 (derivative) @ $217.89 | EDGAR |
| 2025-07-01 | 4 | Enpro Inc. (NPO) | Grant/award (A): 130.51 (derivative) @ $191.55 | EDGAR |
| 2025-06-20 | 4 | Enpro Inc. (NPO) | Grant/award (A): 7 (derivative) @ $185.86 · Grant/award (A): 0.26 (derivative) @ $185.86 | EDGAR |
| 2025-04-17 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 10,860 · Grant/award (A): 50,700 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | Enpro Inc. (NPO) | Grant/award (A): 154.52 (derivative) @ $161.79 | EDGAR |
| 2025-03-20 | 4 | Enpro Inc. (NPO) | Grant/award (A): 7 (derivative) @ $175.76 | EDGAR |
| 2025-02-13 | 4 | Enpro Inc. (NPO) | Grant/award (A): 685 (derivative) @ $182.27 | EDGAR |
| 2025-01-31 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 37,200 (derivative) @ $0 | EDGAR |
| 2024-12-19 | 4 | Enpro Inc. (NPO) | Grant/award (A): 7 (derivative) @ $175.86 | EDGAR |
| 2024-09-19 | 4 | Enpro Inc. (NPO) | Grant/award (A): 8 (derivative) @ $156.77 | EDGAR |
| 2024-06-24 | 4 | Enpro Inc. (NPO) | Grant/award (A): 8 (derivative) @ $146.91 | EDGAR |
| 2024-03-21 | 4 | Enpro Inc. (NPO) | Grant/award (A): 8 (derivative) @ $159.77 | EDGAR |
| 2024-02-15 | 4 | Enpro Inc. (NPO) | Grant/award (A): 803 @ $155.66 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1647102 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →